Overview

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
Phase:
Phase 2
Details
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.
Treatments:
Methamphetamine
Vigabatrin